EFFICACY OFINFLIXIMABIN THE TREATMENTOF CROHN’S DISEASEIN CHILDREN
This paper shows the research results of the biological therapy with chimeric monoclonal antibody to tumor necrosis factor (TNF) (infliximab). 33 children aged 6 to 18 years with various forms of Crohn’s disease were enrolled in the study. Therapy duration ranged from 3 months to 1 year or more. Af...
Saved in:
| Main Authors: | E. G. Tsimbalova, A. S. Potapov, M. M. Venedictova, F. F. Shavrov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2012-01-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/523 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease
by: Seon Young Kim, et al.
Published: (2025-04-01) -
The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study
by: Junya Song, et al.
Published: (2024-12-01) -
Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn’s disease patients
by: Jiao Zheng, et al.
Published: (2025-06-01) -
Development and validation of a nomogram for predicting endoscopic healing in crohn’s disease patients receiving infliximab treatment
by: Lixuan Li, et al.
Published: (2025-07-01) -
Correction: Evaluating the predictive effect of vitamin D on clinical outcomes of infliximab-treated Crohn’s disease patients
by: Jiao Zheng, et al.
Published: (2025-07-01)